Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial
Richard Dodel1, Axel Rominger2, Peter Bartenstein3, Frederik Barkhof4, Kaj Blennow5, Stefan Förster6, Yaroslav Winter1, Jan-Philipp Bach1, Julius Popp7,8, Judith Alferink7, Jens Wiltfang9, Katharina Buerger10, Markus Otto11, Piero Antuono12, Michael Jacoby13, Ralph Richter14, James Stevens15, Isaac Melamed16, Jerome Goldstein17, Stefan Haag18
1University Hospital Giessen and Marburg, Philipps-University Marburg, Marburg, Germany
2Department of Nuclear Medicine, Ludwig-Maximilians-University, Munich, Germany
3Department of Nuclear Medicine, Ludwig Maximilians-University, Munich, Germany
4Image Analysis Centre, VU Medical Center, Amsterdam, Netherlands
5Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden
6Department of Nuclear Medicine, Ludwig–Maximilians–University, Munich, Germany
7Department of Psychiatry, University of Bonn, Bonn, Germany
8Department of Psychiatry, University of Lausanne, Lausanne, Switzerland
9Klinik für Psychiatrie und Psychotherapie, LVR-Kliniken Essen, Kliniken/Institut der Universität Duisburg-Essen, Essen, Germany
10Institute for Stroke and Dementia Research, Klinikum Grosshadern, Ludwig Maximilians-University, Munich, Germany
11Universitätsklinikum Ulm, Abteilung für Neurologie, Ulm, Germany
12Medical College of Wisconsin, Milwaukee, WI, USA
13Mercy Ruan Neurology Clinic, Des Moines, IA, USA
14Tulsa Clinical Research LLC, Tulsa, OK, USA
15Fort Wayne Neurological Center, Fort Wayne, IN, USA
16IMMUNOe International Research Center, Centennial, CO, USA
17San Francisco Clinical Research Center, San Francisco, CA, USA
18Octapharma AG, Lachen, Switzerland
Tài liệu tham khảo
Thông tin
Thông tin xuất bản
The Lancet Neurology
Tập 12
233-243
Thông tin tác giả